EUVIMEDEUVIMED entdecken
Crossref

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

JAMA · 23.06.2026 · 335 (24) · e267399

DOI: 10.1001/jama.2026.7399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, online erschienen am 23.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated whether addition of a locking fluid containing 4% tetrasodium EDTA (t-EDTA) reduced central venous access device (CVAD) complications compared with usual care among adults in intensive care units (ICUs).

Zitieren

APA

(2026). 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA, 335(24), e267399. https://doi.org/10.1001/jama.2026.7399

Vancouver

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. 2026;335(24):e267399. doi:10.1001/jama.2026.7399

BibTeX
@article{euvimed2026,
  title = {4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {24},
  pages = {e267399},
  doi = {10.1001/jama.2026.7399}
}
Kostenlos starten →